A Randomized Trial of Factor VIII and Neutralizing Anti

New England Journal of Medicine
374, 2054-2064
DOI: 10.1056/nejmoa1516437

Citation Report

#	Article	IF	Citations
1	Key insights to understand the immunogenicity of FVIII products. Thrombosis and Haemostasis, 2016, 116, S2-S9.	1.8	10
2	Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A. Journal of Thrombosis and Haemostasis, 2016, 14, 1330-1336.	1.9	17
3	The safety of pharmacologic options for the treatment of persons with hemophilia. Expert Opinion on Drug Safety, 2016, 15, 1391-1400.	1.0	12
4	Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. Blood, 2016, 128, 2007-2016.	0.6	165
5	New therapies for hemophilia. Hematology American Society of Hematology Education Program, 2016, 2016, 650-656.	0.9	33
6	Alteraciones del sistema hemostÃ¡tico. Estrategias diagnÃ³sticas de la patologÃa hemorrÃ¡gica. CoagulopatÃas congÃ©nitas. Medicine, 2016, 12, 1255-1266.	0.0	0
7	Hemophilia Therapy â€" Navigating Speed Bumps on the Innovation Highway. New England Journal of Medicine, 2016, 374, 2087-2089.	13.9	6
8	Use and Future Investigations of Recombinant and Plasma-Derived Coagulation and Anticoagulant Products in the Neonate. Transfusion Medicine Reviews, 2016, 30, 189-196.	0.9	12
9	2017 Clinical trials update: Innovations in hemophilia therapy. American Journal of Hematology, 2016, 91, 1252-1260.	2.0	82
10	Emerging drugs for the treatment of hemophilia A and B. Expert Opinion on Emerging Drugs, 2016, 21, 301-313.	1.0	14
11	Risks of inhibitors from recombinant factor VIII: a quarter of a century to reach the conclusion. Journal of Thrombosis and Haemostasis, 2016, 14, 2073-2074.	1.9	2
12	Plasma is a strategic resource. Transfusion, 2016, 56, 3133-3137.	0.8	39
13	Baby hamster kidney cellâ€"derived recombinant factor VIII: a quarter century of learning and clinical experience. Expert Review of Hematology, 2016, 9, 1151-1164.	1.0	2
14	Prevention of inhibitor development in hemophilia A in 2016. A glimpse into the future?. Thrombosis Research, 2016, 148, 96-100.	0.8	10
15	Reversal of direct oral anticoagulants in hemophilia treatment. Memo - Magazine of European Medical Oncology, 2016, 9, 131-135.	0.3	2
16	Adult, previously untreated patients remain a significant therapeutic challenge. Journal of Thrombosis and Haemostasis, 2016, 14, 2075-2076.	1.9	0
17	Evolution of the Treatments for Hemophilia. Journal of Infusion Nursing, 2016, 39, 218-224.	1.2	5
19	Different impact of factor VIII products on inhibitor development?. Thrombosis Journal, 2016, 14, 31.	0.9	10

#	Article	IF	Citations
20	Response to â€œInnovation in Hemophilia Therapiesâ€”â€˜And Miles to Go, before [We] Sleepâ€™â€•. Seminars in Thrombosis and Hemostasis, 2017, 43, 107-108.	1.5	1
21	Efficacy and safety of a recombinant factor VIII produced from a human cell line (simoctocog alfa). Expert Opinion on Drug Safety, 2017, 16, 405-410.	1.0	4
22	Incidence of lowâ€titre factor VIII inhibitors in patients with haemophilia A: metaâ€analysis of observational studies. Haemophilia, 2017, 23, e87-e92.	1.0	5
23	Production of recombinant coagulation factors: Are humans the best host cells?. Bioengineered, 2017, 8, 462-470.	1.4	21
24	The dynamics of contract plasma fractionation. Biologicals, 2017, 46, 159-167.	0.5	14
25	Large scale studies assessing antiâ€factor <scp>VIII</scp> antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more. British Journal of Haematology, 2017, 178, 20-31.	1.2	10
26	Kreuth <scp>IV</scp>: European consensus proposals for treatment of haemophilia with coagulation factor concentrates. Haemophilia, 2017, 23, 370-375.	1.0	15
27	Reply to the letter by Iorio. Haemophilia, 2017, 23, e248-e249.	1.0	3
28	Biological considerations of plasma-derived and recombinant factor VIII immunogenicity. Blood, 2017, 129, 3147-3154.	0.6	38
29	Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies. Human Gene Therapy, 2017, 28, 654-666.	1.4	15
30	Acquired hemophilia A: a review of recent data and new therapeutic options. Hematology, 2017, 22, 514-520.	0.7	78
31	Factor <scp>VIII</scp> inhibitors: Advances in basic and translational science. International Journal of Laboratory Hematology, 2017, 39, 6-13.	0.7	25
32	Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?. Annals of Hematology, 2017, 96, 1253-1270.	0.8	18
33	Progress in the contemporary management of hemophilia: The new issue of patient aging. European Journal of Internal Medicine, 2017, 43, 16-21.	1.0	26
34	SIPPET trial: the answers. Haemophilia, 2017, 23, 344-345.	1.0	4
35	Hematological Disorders in Children. , 2017, , .		2
36	Moving from parked to neutral(izing). Blood, 2017, 129, 1233-1234.	0.6	0
37	SIPPET: methodology, analysis and generalizability. Haemophilia, 2017, 23, 353-361.	1.0	27

#	Article	IF	Citations
38	The current state of adverse event reporting in hemophilia. Expert Review of Hematology, 2017, 10, 161-168.	1.0	1
39	Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A. Blood, 2017, 129, 1245-1250.	0.6	41
40	Blood Group O Protects against Inhibitor Development in Severe Hemophilia A Patients. Seminars in Thrombosis and Hemostasis, 2017, 43, 069-074.	1.5	12
41	New findings on inhibitor development: from registries to clinical studies. Haemophilia, 2017, 23, 4-13.	1.0	24
42	Plasma products do not solve the inhibitor problem. Haemophilia, 2017, 23, 346-347.	1.0	9
43	Do the SIPPET study results apply to the patients I treat?. Haemophilia, 2017, 23, 348-349.	1.0	12
44	Association of factor <scp>VIII</scp> and factor <scp>IX</scp> mutations, <scp>HLA</scp> Class <scp>II</scp>, tumour necrosis factorâ€Î± and interleukinâ€10 on inhibitor development among Thai haemophilia A and B patients. Haemophilia, 2017, 23, e518-e523.	1.0	0
45	Novel approaches to hemophilia therapy: successes and challenges. Blood, 2017, 130, 2251-2256.	0.6	95
47	A cross-sectional study of complementary and alternative medicine use in patients with coagulation disorders in Southern Iran. Journal of Integrative Medicine, 2017, 15, 359-364.	1.4	3
48	Impacting inhibitor development in hemophilia A. Blood, 2017, 130, 1689-1690.	0.6	3
49	Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?. Blood, 2017, 130, 2463-2468.	0.6	197
50	Simoctocog alfa for the treatment of hemophilia A. Expert Opinion on Biological Therapy, 2017, 17, 1573-1580.	1.4	3
51	Current and emerging factor VIII replacement products for hemophilia A. Therapeutic Advances in Hematology, 2017, 8, 303-313.	1.1	51
52	To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity. Blood Reviews, 2017, 31, 339-347.	2.8	30
53	Meta-analysis on incidence of inhibitors in patients with haemophilia A treated with recombinant factor VIII products. Blood Coagulation and Fibrinolysis, 2017, 28, 627-637.	0.5	20
54	Safety of a pasteurized plasmaâ€derived Factor VIII and von Willebrand factor concentrate: analysis of 33 years of pharmacovigilance data. Transfusion, 2017, 57, 2390-2403.	0.8	13
56	Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis. Blood, 2017, 130, 1757-1759.	0.6	44
57	ASH Meeting 2016: developments in hemostaseology. Memo - Magazine of European Medical Oncology, 2017, 10, 72-75.	0.3	1

#	Article	IF	Citations
58	Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System. Haemophilia, 2017, 23, 207-214.	1.0	56
59	Future of Haemophilia Research in India. Indian Journal of Hematology and Blood Transfusion, 2017, 33, 451-452.	0.3	3
60	Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors. Thrombosis and Haemostasis, 2017, 117, 2274-2282.	1.8	13
61	Hemophilia in focus. Hamostaseologie, 2017, 37, 93-95.	0.9	0
62	Pathogenesis and Treatment of Hemophilia. , 2017, , 189-204.		2
63	The impact of von Willebrand factor on factor VIII memory immune responses. Blood Advances, 2017, 1, 1565-1574.	2.5	10
64	Plasma-derived versus recombinant factor concentrates in PUPs: a never ending debate?. Hamostaseologie, 2017, 37, 53-57.	0.9	7
65	Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?. Journal of Blood Medicine, 2017, Volume 8, 67-73.	0.7	67
66	Hemophilia Care in the Pediatric Age. Journal of Clinical Medicine, 2017, 6, 54.	1.0	39
67	Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin. Thrombosis and Haemostasis, 2017, 117, 33-43.	1.8	30
68	Review of immune tolerance induction in hemophilia A. Blood Reviews, 2018, 32, 326-338.	2.8	51
69	Principles of haemophilia care: The Asiaâ€Pacific perspective. Haemophilia, 2018, 24, 366-375.	1.0	15
70	Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States. Journal of Medical Economics, 2018, 21, 762-769.	1.0	10
71	Product type and other environmental risk factors for inhibitor development in severe hemophilia A. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 220-227.	1.0	20
72	FactorÂVIII products and inhibitor development in previously treated patients with severe or moderately severe hemophiliaÂA: a systematic review. Journal of Thrombosis and Haemostasis, 2018, 16, 1055-1068.	1.9	25
73	Clinical experience with moroctocog alfa (<scp>AF</scp>â€<scp>CC</scp>) in younger paediatric patients with severe haemophilia A: Two openâ€label studies. Haemophilia, 2018, 24, 604-610.	1.0	5
74	Clinical trials and registries in haemophilia: Opponents or collaborators? Comparison of PUP data derived from different data sources. Haemophilia, 2018, 24, 420-428.	1.0	6
75	Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement. Journal of Thrombosis and Haemostasis, 2018, 16, 778-790.	1.9	23

#	Article	IF	Citations
76	Inhibitors in Nonsevere Hemophilia A: What Is Known and Searching for the Unknown. Seminars in Thrombosis and Hemostasis, 2018, 44, 568-577.	1.5	9
77	Viral safety of coagulation factor concentrates: memoirs from an insider. Journal of Thrombosis and Haemostasis, 2018, 16, 630-633.	1.9	8
78	Recent advances in developing specific therapies for haemophilia. British Journal of Haematology, 2018, 181, 161-172.	1.2	32
79	Lonoctocog alfa (rVIII-SingleChain) for the treatment of haemophilia A. Expert Opinion on Biological Therapy, 2018, 18, 87-94.	1.4	5
80	Early cellular interactions and immune transcriptome profiles in human factor VIII-exposed hemophilia A mice. Journal of Thrombosis and Haemostasis, 2018, 16, 533-545.	1.9	24
81	Pharmacokinetic drug evaluation of recombinant factor VIII for the treatment of hemophilia A. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 143-151.	1.5	3
82	A contemporary look at FVIII inhibitor development: still a great influence on the evolution of hemophilia therapies. Expert Review of Hematology, 2018, 11, 87-97.	1.0	14
83	Low incidence of factor <scp>VIII</scp> inhibitors in previously untreated patients with severe haemophilia A treated with octanate^{Â®}: Final report from a prospective study. Haemophilia, 2018, 24, 221-228.	1.0	8
84	The inflammatory reflex and neural tourniquet: harnessing the healing power of the vagus nerve. Bioelectronics in Medicine, 2018, 1, 29-38.	2.0	4
85	After the <scp>SIPPET</scp> study: Position paper of the Co<scp>METH</scp>, the French society of haemophilia. Haemophilia, 2018, 24, e55-e57.	1.0	1
86	European principles of inhibitor management in patients with haemophilia. Orphanet Journal of Rare Diseases, 2018, 13, 66.	1.2	33
87	Tolerogenic properties of the Fc portion of IgG and its relevance to the treatment and management of hemophilia. Blood, 2018, 131, 2205-2214.	0.6	26
88	Interpreting data on inhibitor development from previously untreated patient studies, beware of premature conclusions. Haemophilia, 2018, 24, 177-179.	1.0	2
89	Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A. Haematologica, 2018, 103, 179-189.	1.7	48
90	Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin Î±â€chain crosslinking. Journal of Thrombosis and Haemostasis, 2018, 16, 131-141.	1.9	6
91	A Retrospective Study of the Cytokine Profile Changes in Mice with FVIII Inhibitor Development After Adeno-Associated Virusâ€“Mediated Gene Therapy in a Hemophilia A Mouse Model. Human Gene Therapy, 2018, 29, 381-389.	1.4	9
92	Comparative profiling of HLA-DR and HLA-DQ associated factor VIII peptides presented by monocyte-derived dendritic cells. Haematologica, 2018, 103, 172-178.	1.7	23
93	Immunogenicity, efficacy and safety of Nuwiq^{Â®} (humanâ€cl rh<scp>FVIII</scp>) in previously untreated patients with severe haemophilia Aâ€”Interim results from the NuProtect Study. Haemophilia, 2018, 24, 211-220.	1.0	26

#	Article	IF	Citations
94	Major bleeding disorders: diagnosis, classification, management and recent developments in haemophilia. Archives of Disease in Childhood, 2018, 103, 509-513.	1.0	5
95	A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A. Clinical Pharmacokinetics, 2018, 57, 1123-1134.	1.6	65
96	Identification of aggregates in therapeutic formulations of recombinant fullâ€length factor VIII products by sedimentation velocity analytical ultracentrifugation. Journal of Thrombosis and Haemostasis, 2018, 16, 303-315.	1.9	11
97	Inhibitors in Hemophilia A: A Pharmacoeconomic Perspective. Seminars in Thrombosis and Hemostasis, 2018, 44, 561-567.	1.5	6
98	SIPPET: insights into factor VIII immunogenicity. Journal of Thrombosis and Haemostasis, 2018, 16, 36-38.	1.9	1
99	Timing and severity of inhibitor development in recombinant versus plasmaâ€derived factor VIII concentrates: a SIPPET analysis. Journal of Thrombosis and Haemostasis, 2018, 16, 39-43.	1.9	39
100	Influence of medical insurance schemes and charity assistance projects on regular prophylaxis treatment of the boys with severe haemophilia A in China. Haemophilia, 2018, 24, 126-133.	1.0	10
101	The Neural Tourniquet. , 2018, , 1531-1539.		0
102	An overview of plasma fractionation. Annals of Blood, 0, 3, 33-33.	0.4	22
103	Factor VIII manufactured from plasmaâ€”the ups and downs, and the up again: a personal journeyâ€”part 1: history of the development of plasma-derived factor VIII therapies. Annals of Blood, 2018, 3, 17-17.	0.4	1
104	The organization of transfusion and fractionation in France and its regulation. Annals of Blood, 0, 3, 37-37.	0.4	2
105	Navigating Speed Bumps on the Innovation Highway in Hemophilia Therapeutics. HemaSphere, 2018, 2, e144.	1.2	6
106	Role of virus inactivated cryoprecipitate in the treatment of bleeding disorders. Annals of Blood, 2018, 3, 21-21.	0.4	3
107	Role of the mini-pool cryoprecipitate technology for cost-saving and guarantee of local Factor VIII, Von Willebrand Factor and Fibrinogen product supply: Egypt experience. Annals of Blood, 0, 3, 22-22.	0.4	4
108	Supply and demand for hemophilia treatmentsâ€”Systems-based approaches to mitigate the risk. Transfusion and Apheresis Science, 2018, 57, 731-734.	0.5	4
109	The importance of inhibitor eradication in clinically complicated hemophilia A patients. Expert Review of Hematology, 2018, 11, 857-862.	1.0	16
110	Emicizumab for hemophilia A with factor VIII inhibitors. Expert Review of Hematology, 2018, 11, 835-846.	1.0	22
111	How I approach: Previously untreated patients with severe congenital hemophilia A. Pediatric Blood and Cancer, 2018, 65, e27466.	0.8	4

#	Article	IF	Citations
112	The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2018, 16, 2530-2533.	1.9	53
113	New technologies in gene therapy for inducing immune tolerance in hemophilia A. Expert Review of Clinical Immunology, 2018, 14, 1013-1019.	1.3	7
114	A Practical Guide to the Management of the Fetus and Newborn With Hemophilia. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 29S-41S.	0.7	13
115	Emerging therapies for hemophilia: controversies and unanswered questions. F1000Research, 2018, 7, 489.	0.8	29
116	Clinicopathological parameters influencing inhibitor development in patients with hemophilia A receiving on-demand therapy. Therapeutic Advances in Hematology, 2018, 9, 213-226.	1.1	10
117	Guidelines for the management of haemophilia in Egypt. The Journal of Haemophilia Practice, 2018, 5, 83-92.	0.2	1
118	Emicizumab should be prescribed independent of immune tolerance induction. Blood Advances, 2018, 2, 2783-2786.	2.5	26
119	Novel therapeutics for hemophilia and other bleeding disorders. Blood, 2018, 132, 23-30.	0.6	46
120	Letter to the Editor of Haemophilia. Haemophilia, 2018, 24, e246-e248.	1.0	1
121	Evolving Complexity in Hemophilia Management. Pediatric Clinics of North America, 2018, 65, 407-425.	0.9	10
122	Principles of haemophilia care: The Asiaâ€Pacific perspective.. Haemophilia, 2018, 24, e245-e246.	1.0	1
123	International collaboration is needed to reduce the risk for inhibitors in <scp>PUP</scp>s with severe haemophilia A. Haemophilia, 2018, 24, e242-e243.	1.0	0
124	Biochemical characterization and immunogenicity of Neureight, a recombinant full-length factor VIII produced by fed-batch process in disposable bioreactors. Cellular Immunology, 2018, 331, 22-29.	1.4	4
125	Risk factors for inhibitor development in severe hemophilia A. Thrombosis Research, 2018, 168, 20-27.	0.8	67
126	Genetic Risk Factors and Inhibitor Development in Hemophilia: What Is Known and Searching for the Unknown. Seminars in Thrombosis and Hemostasis, 2018, 44, 509-516.	1.5	9
127	Perinatal, Neonatal, and Pediatric Transfusionâ€"Principles and Practice. , 2018, , 219-240.		0
128	Antibodies to FVIII. , 2018, , 119-134.		0
129	Inhibitors in Hemophilias. , 2018, , 2023-2033.e5.		1

#	Article	IF	Citations
130	Optimizing bleed prevention throughout the lifespan: Womb to Tomb. Haemophilia, 2018, 24, 76-86.	1.0	4
131	Preventing or Eradicating Factor VIII Antibody Formation in Patients with Hemophilia A: What Can We Learn from Other Disorders?. Seminars in Thrombosis and Hemostasis, 2018, 44, 531-543.	1.5	9
132	Comment on: Interpreting data on inhibitor development from previously untreated patient studies, beware of premature conclusions. Haemophilia, 2018, 24, e273-e275.	1.0	0
133	The immunogenicity of ReFacto <scp>AF</scp> (moroctocog alfa <scp>AF</scp>â€<scp>CC</scp>) in previously untreated patients with haemophilia A in the United Kingdom. Haemophilia, 2018, 24, 896-901.	1.0	11
134	Bitter progress in the treatment of haemophilia A in low-income countries. Lancet Haematology,the, 2018, 5, e239.	2.2	8
135	The current and future role of plasma-derived clotting factor concentrate in the treatment of haemophilia A. Transfusion and Apheresis Science, 2018, 57, 502-506.	0.5	7
136	Consensus Statement of the Indian Academy of Pediatrics in Diagnosis and Management of Hemophilia. Indian Pediatrics, 2018, 55, 582-590.	0.2	11
137	Prevention and Management of Bleeding Episodes in Children with Hemophilia. Paediatric Drugs, 2018, 20, 455-464.	1.3	13
138	Inhibitor Formation in Congenital Hemophilia A: an Immunological Perspective. Seminars in Thrombosis and Hemostasis, 2018, 44, 517-530.	1.5	10
139	Choices of factor <scp>VIII</scp> products in previously untreated patients with haemophilia A: A global survey. Haemophilia, 2018, 24, e266-e268.	1.0	0
140	The inhibitors â€“ a challenge for the management of patients with hereditary haemophilia A. Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne, 2018, 56, 143-152.	0.3	0
141	Optimized Adeno-Associated Viral-Mediated Human Factor VIII Gene Therapy in Cynomolgus Macaques. Human Gene Therapy, 2018, 29, 1364-1375.	1.4	18
142	Prophylactic versus on-demand treatments for hemophilia: advantages and drawbacks. Expert Review of Hematology, 2018, 11, 567-576.	1.0	19
143	Pharmacokinetic-based prediction of real-life dosing of extended half-life clotting factor concentrates on hemophilia. Therapeutic Advances in Hematology, 2018, 9, 149-162.	1.1	11
144	Bioengineered molecules for the management of haemophilia: Promise and remaining challenges. Haemophilia, 2018, 24, 68-75.	1.0	10
145	Strategies for Blood Product Management, Reducing Transfusions, and Massive Blood Transfusion. , 2019, , 257-280.e13.		5
146	Pharmacokinetic and safety considerations when switching from standard to extended half-life clotting factor concentrates in hemophilia. Expert Review of Hematology, 2019, 12, 883-892.	1.0	2
147	Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A. Blood, 2019, 134, 317-320.	0.6	71

#	Article	IF	Citations
148	Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects. TH Open, 2019, 03, e123-e131.	0.7	4
149	Impact of the Survey of Inhibitors in Plasmaâ€Product Exposed Toddlers (SIPPET) study and its post hoc analyses on clinical practice in the United States: A survey of Haemophilia and Thrombosis Research Society members. Haemophilia, 2019, 25, 764-772.	1.0	7
150	Efficacy and safety of simoctocog alfa (NuwiqÂ®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program. Therapeutic Advances in Hematology, 2019, 10, 204062071985847.	1.1	18
151	When innovation goes fast. The case of hemophilia. Current Opinion in Pharmacology, 2019, 45, 95-101.	1.7	5
153	A multicentre, openâ€label study of emicizumab given every 2 or 4Âweeks in children with severe haemophilia A without inhibitors. Haemophilia, 2019, 25, 979-987.	1.0	103
154	Hemophilia A with inhibitor: Immune tolerance induction (ITI) in the mirror of time. Transfusion and Apheresis Science, 2019, 58, 578-589.	0.5	17
155	Antibodies in the Treatment of Haemophilia Aâ€"A Biochemical Perspective. Hamostaseologie, 2019, 39, 036-041.	0.9	2
156	Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events. Journal of Medical Economics, 2019, 22, 1328-1337.	1.0	15
157	Safety of recombinant coagulation factors in treating hemophilia. Expert Opinion on Drug Safety, 2019, 18, 75-85.	1.0	12
158	Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy. Molecular Therapy - Methods and Clinical Development, 2019, 12, 184-201.	1.8	39
159	Vaccination in patients with haemophiliaâ€"Results from an online survey among haemophilia treatment centres in Germany. Haemophilia, 2019, 25, e304-e306.	1.0	5
160	Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A. PLoS ONE, 2019, 14, e0218258.	1.1	12
161	How I treat children with haemophilia and inhibitors. British Journal of Haematology, 2019, 186, 400-408.	1.2	33
162	Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies. Haemophilia, 2019, 25, 398-407.	1.0	27
163	The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. Haemophilia, 2019, 25, 676-684.	1.0	75
164	Consensus statements on vaccination in patients with haemophiliaâ€"Results from the Italian haemophilia and vaccinations (HEVA) project. Haemophilia, 2019, 25, 656-667.	1.0	16
165	Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis. Blood Reviews, 2019, 35, 43-50.	2.8	57
166	New monoclonal/bi-specific antibodies: Reshaping transfusion medicine beyond replacement. Transfusion and Apheresis Science, 2019, 58, 208-211.	0.5	3

#	Article	IF	Citations
167	Why plasmaâ€derived factor VIII?. Haemophilia, 2019, 25, e183-e185.	1.0	0
168	An update on the â€˜danger theoryâ€™ in inhibitor development in hemophilia A. Expert Review of Hematology, 2019, 12, 335-344.	1.0	15
169	Case Report: Development of Factor VIII Inhibitor in a Patient with an Uncommon de novo Mutation in the Factor VIII Gene. Acta Haematologica, 2019, 141, 129-134.	0.7	1
170	Amino acid metabolism as drug target in autoimmune diseases. Autoimmunity Reviews, 2019, 18, 334-348.	2.5	48
171	Factor products. JACCP Journal of the American College of Clinical Pharmacy, 2019, 2, 82-86.	0.5	0
173	The ongoing imperative for immune tolerance induction in inhibitor management. Haemophilia, 2019, 25, 183-186.	1.0	9
174	Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products. Blood Advances, 2019, 3, 1429-1440.	2.5	20
175	Epidemiology and Treatment of Patients with Haemophilia in Austriaâ€"Update from the Austrian Haemophilia Registry. Hamostaseologie, 2019, 39, 284-293.	0.9	6
176	Research on Accelerating Application Technology of Centralized ERP System Based on HANA. Journal of Physics: Conference Series, 2019, 1314, 012143.	0.3	0
177	Re-personalization and stratification of hemophilia care in an evolving treatment landscape. Hematology, 2019, 24, 737-741.	0.7	6
178	Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia A in Italy: Characteristics and Clinical Benefits. Frontiers in Medicine, 2019, 6, 261.	1.2	25
179	Mechanistic Insights into Factor VIII Immune Tolerance Induction via Prenatal Cell Therapy in Hemophilia A. Current Stem Cell Reports, 2019, 5, 145-161.	0.7	3
180	Perioperative laboratory monitoring in congenital haemophilia patients with inhibitors. Blood Coagulation and Fibrinolysis, 2019, 30, 309-323.	0.5	1
181	Thrombin generation assay for testing hemostatic effect of factor VIII concentrates in patients with hemophilia A and inhibitors: In vitro results from the PredicTGA study. Thrombosis Research, 2019, 174, 84-87.	0.8	4
182	Inhibitor incidence in haemophilia A under exclusive use of a thirdâ€generation recombinant factor <scp>VIII</scp> concentrate: results of the <scp>HEMFIL</scp> Cohort Study. British Journal of Haematology, 2019, 186, 152-155.	1.2	5
183	Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance?. Haematologica, 2019, 104, 236-244.	1.7	23
184	Continuous infusion of simoctocog alfa in haemophilia A patients undergoing surgeries. Haemophilia, 2019, 25, 54-59.	1.0	4
185	Prevalence of FVIII inhibitors in severe haemophilia A patients: Effect of treatment and genetic factors in an Indian population. Haemophilia, 2019, 25, 67-74.	1.0	9

#	Article	IF	Citations
186	Administration of recombinant FVIIa (rFVIIa) to concizumabâ€dosed monkeys is safe, and concizumab does not affect the potency of rFVIIa in hemophilic rabbits. Journal of Thrombosis and Haemostasis, 2019, 17, 460-469.	1.9	8
187	De novo design of potent and selective mimics of IL-2 and IL-15. Nature, 2019, 565, 186-191.	13.7	362
188	Over two decades of orthopaedic surgery in patients with inhibitorsâ€"Quantifying the complication of bleeding. Haemophilia, 2019, 25, 21-32.	1.0	2
189	Hemophilia A. , 2019, , 677-683.		0
190	Hemophilia A and Hemophilia B. , 2019, , 39-58.		2
191	Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity. International Journal of Hematology, 2020, 111, 20-30.	0.7	36
192	Future of Haemophilia Research in India. Indian Journal of Hematology and Blood Transfusion, 2020, 36, 1-2.	0.3	7
193	Hemophilia â€“ Impact of Recent Advances on Management. Indian Journal of Pediatrics, 2020, 87, 134-140.	0.3	3
194	Quantitative HLAâ€classâ€IIâ€factor VIII (FVIII) peptidomic variation in dendritic cells correlates with the immunogenic potential of therapeutic FVIII proteins in hemophilia A. Journal of Thrombosis and Haemostasis, 2020, 18, 201-216.	1.9	3
195	Inhibitor epidemiology and geneticâ€related risk factors in people with haemophilia from CÃ´te dâ€™Ivoire. Haemophilia, 2020, 26, 79-85.	1.0	3
196	Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial. Haemophilia, 2020, 26, 64-72.	1.0	17
197	Healthâ€related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitorsâ€"Results from the HAVEN 2 study. Haemophilia, 2020, 26, 1009-1018.	1.0	16
201	Arthroplasty in haemophilia: Doubleâ€edged sword in low/middleâ€income countries. Haemophilia, 2020, 26, e344-e345.	1.0	0
202	FVIII Immunogenicityâ€"Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A. Frontiers in Immunology, 2020, 11, 1498.	2.2	0
203	WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia, 2020, 26, 1-158.	1.0	915
204	The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and Challenges. Hamostaseologie, 2020, 40, 311-321.	0.9	16
205	Emicizumab-Induced Seronegative Full-House Lupus Nephritis in a Child. Pediatrics, 2020, 146, .	1.0	4
206	Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy. Haemophilia, 2020, 26, 958-965.	1.0	11

#	Article	IF	Citations
207	Management of previously untreated patients with severe haemophilia A preferentially treated with recombinant factor VIII products: Two French centres' realâ€life experience. Haemophilia, 2020, 26, e349-e352.	1.0	1
208	Supply and demand for plasmaâ€derived medicinal products â€•A critical reassessment amid the <scp>COVID</scp>â€19 pandemic. Transfusion, 2020, 60, 2748-2752.	0.8	36
209	Singleâ€domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors. EMBO Molecular Medicine, 2020, 12, e11298.	3.3	20
211	The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development. Blood Advances, 2020, 4, 5785-5796.	2.5	22
213	Prevalence and Incidence of Non-neutralizing Antibodies in Congenital Hemophilia Aâ€" A Systematic Review and Meta-Analysis. Frontiers in Immunology, 2020, 11, 563.	2.2	12
214	Perinatal Management of Haemophilia. Hamostaseologie, 2020, 40, 226-232.	0.9	8
215	Unexpected enhancement of FVIII immunogenicity by endothelial expression in lentivirus-transduced and transgenic mice. Blood Advances, 2020, 4, 2272-2285.	2.5	3
216	The availability of new drugs for hemophilia treatment. Expert Review of Clinical Pharmacology, 2020, 13, 721-738.	1.3	5
217	Prophylaxis for hemophilia A without inhibitors: treatment options and considerations. Expert Review of Hematology, 2020, 13, 731-743.	1.0	16
218	Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 1109-1120.	0.5	10
219	Investigator clinical trials: How can we ask the question?. Haemophilia, 2020, 26, 20-21.	1.0	1
220	Development of inhibitors in hemophilia A: An illustrated review. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 752-760.	1.0	11
221	An evaluation of the safety and efficacy of turoctocog alfa for hemophilia A. Expert Review of Hematology, 2020, 13, 303-311.	1.0	1
222	Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigms. Expert Review of Hematology, 2020, 13, 313-321.	1.0	15
223	Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a caseâ€'control study. British Journal of Haematology, 2020, 189, 1182-1191.	1.2	3
224	Hemophilia A Inhibitor Subjects Show Unique PBMC Gene Expression Profiles That Include Up-Regulated Innate Immune Modulators. Frontiers in Immunology, 2020, 11, 1219.	2.2	5
225	Inhibitor development in previously untreated patients with severe haemophilia: A comparison of included patients and outcomes between a clinical study and a registryâ€based study. Haemophilia, 2020, 26, 809-816.	1.0	2
226	Clinical Care of Bone Health in Patients on the Immune Tolerance Inductionâ€™s Protocols With an Immunosuppressive Agent for Inhibitor Eradication in Hemophilia. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962091395.	0.7	3

#	Article	IF	Citations
227	How Do I Counsel Parents of a Newly Diagnosed Boy with Haemophilia A?. Hamostaseologie, 2020, 40, 088-096.	0.9	5
228	Advances in knowledge of inhibitor formation in severe haemophilia A. British Journal of Haematology, 2020, 189, 39-53.	1.2	25
229	Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A . Drug Design, Development and Therapy, 2020, Volume 14, 469-481.	2.0	11
230	Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies. Frontiers in Immunology, 2019, 10, 3078.	2.2	17
231	Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A. Frontiers in Immunology, 2020, 11, 618.	2.2	22
232	octanateÂ®: over 20â€‰years of clinical experience in overcoming challenges in haemophilia A treatment. Therapeutic Advances in Hematology, 2020, 11, 204062072091469.	1.1	3
233	Guidelines for the prophylaxis of haemophilia A and B: new horizons and ambitions. British Journal of Haematology, 2020, 190, 643-644.	1.2	4
234	Development of Haemophilia Treatment in the Eastern Part of Germany over the Last Decade in the Kompetenznetz HÃmorrhagische Diathese Ost (KHDO). Hamostaseologie, 2020, 40, 119-127.	0.9	3
235	A molecular jewel for hemophilia A treatment. Blood, 2020, 135, 1417-1419.	0.6	2
236	Escape or Fight: Inhibitors in Hemophilia A. Frontiers in Immunology, 2020, 11, 476.	2.2	8
237	Delivering on the promise of gene therapy for haemophilia. Haemophilia, 2021, 27, 114-121.	1.0	21
238	Inhibitorsâ€”Recent insights. Haemophilia, 2021, 27, 28-36.	1.0	6
239	Longâ€term safety and efficacy of emicizumab for up to 5.8 years and patientsâ€™ perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A. Haemophilia, 2021, 27, 81-89.	1.0	24
240	Incidence of inhibitor development in PUPs with severe Haemophilia A in the CEE region between 2005 and 2015. Thrombosis Research, 2021, 198, 196-203.	0.8	5
241	IgG subclasses as biomarkers for persistence of factor VIII inhibitors in previously untreated patients with severe haemophilia A. British Journal of Haematology, 2021, 192, 621-625.	1.2	1
242	X Chromosome inactivation: a modifier of factor VIII and IX plasma levels and bleeding phenotype in Haemophilia carriers. European Journal of Human Genetics, 2021, 29, 241-249.	1.4	17
243	Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: Recommendations from a German expert panel. Haemophilia, 2021, 27, e305-e313.	1.0	23
244	Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors. Expert Review of Hematology, 2021, 14, 143-148.	1.0	16

#	Article	IF	Citations
245	Immune Responses to Plasma-Derived Versus Recombinant FVIII Products. Frontiers in Immunology, 2020, 11, 591878.	2.2	9
246	Bleeding Disorders. , 2021, , 293-311.		0
247	Characterization of the neutralizing antiâ€emicizumab antibody in a patient with hemophilia A and inhibitor. Journal of Thrombosis and Haemostasis, 2021, 19, 711-718.	1.9	19
248	Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study. Thrombosis and Haemostasis, 2021, 121, 1400-1408.	1.8	14
249	ABO Blood Group and Inhibitor Risk in Severe Hemophilia A Patients: A Study from the Italian Association of Hemophilia Centers. Seminars in Thrombosis and Hemostasis, 2021, 47, 084-089.	1.5	3
250	Characterization of protein unable to bind von Willebrand factor in recombinant factor VIII products. Journal of Thrombosis and Haemostasis, 2021, 19, 954-966.	1.9	4
251	Patients with haemophilia A with inhibitors in China: a national realâ€world analysis and followâ€up. British Journal of Haematology, 2021, 192, 900-908.	1.2	7
252	Maternal Hematologic Conditions and Fetal/Neonatal Outcomes of Pregnancy. NeoReviews, 2021, 22, e95-e103.	0.4	0
254	Hemostatic therapy as a management strategy for acquired hemophilia: what does the future hold?. Expert Review of Hematology, 2021, 14, 263-270.	1.0	3
255	Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study. Haemophilia, 2021, 27, 358-365.	1.0	9
256	Exposureâ€“Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII. Clinical Pharmacokinetics, 2021, 60, 931-941.	1.6	15
257	Tratamiento moderno de la hemofilia y el desarrollo de terapias innovadoras. Investigacion Clinica, 2021, 62, 73-95.	0.0	0
258	Recombinant factor VIII Fc for the treatment of haemophilia A. European Journal of Haematology, 2021, 106, 745-761.	1.1	11
259	Neonatal coagulopathies: A review of established and emerging treatments. Experimental Biology and Medicine, 2021, 246, 1447-1457.	1.1	4
260	B cellâ€“activating factor modulates the factor VIII immune response in hemophilia A. Journal of Clinical Investigation, 2021, 131, .	3.9	10
261	Role of Regulatory Cells in Immune Tolerance Induction in Hemophilia A. HemaSphere, 2021, 5, e557.	1.2	2
262	Performance of a clinical risk prediction model for inhibitor formation in severe haemophilia A. Haemophilia, 2021, 27, e441-e449.	1.0	1
263	Characterisation and application of recombinant FVIIIâ€neutralising antibodies from haemophilia A inhibitor patients. British Journal of Haematology, 2021, 193, 976-987.	1.2	3

#	Article	IF	Citations
264	Bispecific antibodies for the treatment of hemophilia A. Expert Opinion on Biological Therapy, 2022, 22, 1029-1042.	1.4	2
265	The Bâ€Natural studyâ€"The outcome of immune tolerance induction therapy in patients with severe haemophilia B. Haemophilia, 2021, 27, 802-813.	1.0	11
266	A survey on practice of circumcision in children with severe haemophilia in Eastern Mediterranean Region. Haemophilia, 2021, 27, e617-e619.	1.0	0
267	Haemophilia. Nature Reviews Disease Primers, 2021, 7, 45.	18.1	103
268	Recent Advances in the Treatment of Hemophilia: A Review. Biologics: Targets and Therapy, 2021, Volume 15, 221-235.	3.0	21
269	Trends in the Use of Conventional and New Pharmaceuticals for Hemophilia Treatments Among Medicaid Enrollees, 2005-2020. JAMA Network Open, 2021, 4, e2112044.	2.8	2
270	Risk factors for antibody formation in children with hemophilia: methodological aspects and clinical characteristics of the HEMFIL cohort study. Blood Coagulation and Fibrinolysis, 2021, 32, 443-450.	0.5	2
271	Phage display broadly identifies inhibitorâ€reactive regions in von Willebrand factor. Journal of Thrombosis and Haemostasis, 2021, 19, 2702-2709.	1.9	4
272	Haemophilia: factoring in new therapies. British Journal of Haematology, 2021, 194, 835-850.	1.2	17
273	FVIII at the crossroad of coagulation, bone and immune biology: Emerging evidence of biological activities beyond hemostasis. Drug Discovery Today, 2022, 27, 102-116.	3.2	9
274	Treatmentâ€related risk factors for inhibitor development in nonâ€severe hemophilia A after 50 cumulative exposure days: A caseâ€control study. Journal of Thrombosis and Haemostasis, 2021, 19, 2171-2181.	1.9	8
275	Identification of a modified coagulation factor X with enhanced activation properties as potential hemostatic agent. Blood Cells, Molecules, and Diseases, 2021, 89, 102570.	0.6	1
276	Severe haemophilia A in a preterm girl with Turner syndrome: case report â€" a diagnostic and therapeutic challenge for a paediatrician (Part 2). Italian Journal of Pediatrics, 2021, 47, 157.	1.0	2
277	An update of the current pharmacotherapeutic armamentarium for hemophilia A. Expert Opinion on Pharmacotherapy, 2022, 23, 129-138.	0.9	3
278	Commentary on â€œDevelopment of a novel fully functional coagulation factor VIII with reduced immunogenicity utilizing an in silico prediction and deimmunization approachâ€•â€•Will we ever be able to avoid inhibitor formation in hemophilia A?. Journal of Thrombosis and Haemostasis, 2021, 19, 2125-2126.	1.9	0
279	Tolerogenic form of Factor VIII to prevent inhibitor development in the treatment of Hemophilia A. Journal of Thrombosis and Haemostasis, 2021, 19, 2744-2750.	1.9	5
280	Clinical trials for genetic diseases in Latin America. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2021, 187, 381-387.	0.7	0
281	Prophylaxis in children with haemophilia in an evolving treatment landscape. Haemophilia, 2021, 27, 889-896.	1.0	9

#	Article	IF	Citations
282	Induction of Tolerance to Therapeutic Proteins With Antigen-Processing Independent T Cell Epitopes: Controlling Immune Responses to Biologics. Frontiers in Immunology, 2021, 12, 742695.	2.2	6
283	Post-authorization pharmacovigilance for hemophilia in Europe and the USA: Independence and transparency are keys. Blood Reviews, 2021, 49, 100828.	2.8	8
284	The EHA Research Roadmap: Blood Coagulation and Hemostatic Disorders. HemaSphere, 2021, 5, e643.	1.2	3
285	Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies. ACS Nano, 2021, 15, 14022-14048.	7.3	189
286	Long-Term Safety and Efficacy Data of a Plasma-Derived Factor VIII Concentrate with von Willebrand Factor for Treatment of Patients with Hemophilia A Covering 18 Years. Hamostaseologie, 2019, 39, 360-367.	0.9	2
287	The endothelial cell receptor stabilin-2 regulates VWF-FVIII complex half-life and immunogenicity. Journal of Clinical Investigation, 2018, 128, 4057-4073.	3.9	67
288	Comparative glycosylation mapping of plasma-derived and recombinant human factor VIII. PLoS ONE, 2020, 15, e0233576.	1.1	13
289	Gene Therapy for Hemophilia A: Where We Stand. Current Gene Therapy, 2020, 20, 142-151.	0.9	7
290	High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis. Blood Transfusion, 2018, 16, 215-220.	0.3	12
291	Non-factor replacement therapy for haemophilia: a current update. Blood Transfusion, 2018, 16, 457-461.	0.3	46
292	Treatment Options in Hemophilia. Deutsches Ärzteblatt International, 2019, 116, 791-798.	0.6	12
293	Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A. Haematologica, 2019, 104, e369-e372.	1.7	4
294	Tolerating Factor VIII: Recent Progress. Frontiers in Immunology, 2019, 10, 2991.	2.2	52
295	Epidemiological Challenges in Rare Bleeding Disorders: FVIII Inhibitor Incidence in Haemophilia A Patientsâ€”A Known Issue of Unknown Origin. International Journal of Environmental Research and Public Health, 2021, 18, 225.	1.2	5
296	Italian Registry of Congenital Bleeding Disorders. Journal of Clinical Medicine, 2017, 6, 0034.	1.0	14
297	Extended Half-Life (EHL) Coagulation Factors: A New Era in the Management of Haemophilia Patients. Turkish Journal of Haematology, 2019, 36, 141-154.	0.2	23
299	Congenital hemophilia A with low activity of factor XII: a case report and literature review. Italian Journal of Pediatrics, 2021, 47, 204.	1.0	0
301	Progress of Hemophilia A Therapeutics in Korea. Clinical Pediatric Hematology-Oncology, 2018, 25, 17-22.	0.0	1

#	Article	IF	Citations
302	Living with an inhibitor: Results from the Study of Haemophilia Experiences, Results and Opportunities in Children and young adults with long-standing inhibitors (the SO-HEROIC study). The Journal of Haemophilia Practice, 2018, 5, 24-34.	0.2	0
303	â€œPrevalence of Inhibitors in Hemophilia Patients and its Clinical Implicationsâ€: A Study of 276 Patients in Western India. Global Journal of Transfusion Medicine, 2019, 4, 168.	0.0	3
306	Prevalence of FVIII Inhibitors Among Children with Hemophilia A: Experience at the Jordanian Royal Medical Services. Medicinski Arhiv = Medical Archives = Archives De MÃ©decine, 2020, 74, 187.	0.4	0
308	The increased demand for plasma-derived factor VIII in Italy between 2011 and 2014 is attributable to treatment of adult patients rather than paediatric or previously unexposed patients with severe haemophilia A. Blood Transfusion, 2017, 15, 281-282.	0.3	5
309	Italian consumption of plasma-derived factor VIII after the SIPPET study. Blood Transfusion, 2017, 15, 283-284.	0.3	1
310	Recommendations for factor VIII product source to treat patients with haemophilia A. Blood Transfusion, 2017, 15, 285.	0.3	6
311	Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients. Journal of Pharmacopuncture, 2018, 21, 76-81.	0.4	0
312	Factors affecting the quality, safety and marketing approval of clotting factor concentrates for haemophilia. Blood Transfusion, 2018, 16, 525-534.	0.3	5
317	Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies for Hemophilia A Patients. International Journal of Molecular and Cellular Medicine, 2020, 9, 33-50.	1.1	4
318	Disorders of coagulation. , 2022, , 287-340.		1
319	Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors. Blood Advances, 2022, 6, 946-958.	2.5	8
320	Hemophilia: The Past, the Present, and the Future. Pediatrics in Review, 2021, 42, 672-683.	0.2	3
321	Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients. Journal of Pharmacopuncture, 2018, 21, 76-81.	0.4	1
322	Bleeding Disorders. , 2021, , .		0
323	Effects of replacement therapies with clotting factors in patients with hemophilia: A systematic review and meta-analysis. PLoS ONE, 2022, 17, e0262273.	1.1	4
324	Association of ZFHX3 Genetic Polymorphisms and Extra-Pulmonary Vein Triggers in Patients With Atrial Fibrillation Who Underwent Catheter Ablation. Frontiers in Physiology, 2021, 12, 807545.	1.3	0
326	The prevalence of anti-factor VIII and anti-factor IX antibodies among patients with hemophilia in Rabat, Morocco: a single center experience. Pan African Medical Journal, 2022, 41, 126.	0.3	1
327	Genetic variants at the chromosomal region 2q21.3 underlying inhibitor development in patients with severe haemophilia A. Haemophilia, 2022, 28, 270-277.	1.0	1

#	Article	IF	Citations
328	Shortage of plasma-derived products: a looming crisis?. Blood, 2022, 139, 3222-3225.	0.6	15
329	PerquiriÃ§Ã£o clÃnica e epidemiolÃ³gica do tratamento de pacientes com aloaticorpos inibidores em hemofilia do tipo A atendidos em um hemocentro no nordeste brasileiro. Research, Society and Development, 2022, 11, e26711427435.	0.0	0
330	A novel nextâ€generation FVIIIa mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: Results from safety studies in cynomolgus monkeys. Journal of Thrombosis and Haemostasis, 2022, 20, 1312-1324.	1.9	18
331	Therapeutic correction of hemophilia A using 2D endothelial cells and multicellular 3D organoids derived from CRISPR/Cas9-engineered patient iPSCs. Biomaterials, 2022, 283, 121429.	5.7	16
332	How do we optimally utilize factor concentrates in persons with hemophilia?. Hematology American Society of Hematology Education Program, 2021, 2021, 206-214.	0.9	4
334	Structural, functional, and immunogenicity implications of F9 gene recoding. Blood Advances, 2022, 6, 3932-3944.	2.5	4
335	First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results. Blood, 2022, 139, 3699-3707.	0.6	13
352	Emicizumab for All Pediatric Patients with Severe Hemophilia A. Hamostaseologie, 2022, 42, 104-115.	0.9	5
353	Neutralizing Antibodies Against Factor VIII Can Occur Through a Non-Germinal Center Pathway. Frontiers in Immunology, 2022, 13, .	2.2	2
354	Inhibitors: Diagnostic challenges, unknowns of inhibitor development, treatment of bleeding and surgery, and insights into diagnosis and treatment in China. Haemophilia, 2022, 28, 111-118.	1.0	0
355	The legacy of haemophilia: Memories and reflections from three survivors. Haemophilia, 2022, , .	1.0	2
356	Plasmaâ€derived FVIII/VWF complex shows higher protection against inhibitors than isolated FVIII after infusion in haemophilic patients: A translational study. Haemophilia, 0, , .	1.0	2
357	Postâ€procedural bleeding rate and haemostatic treatment use for dental procedures before and after the implementation of a standardized protocol for people with inherited bleeding disorders. Haemophilia, 0, , .	1.0	1
358	Immune tolerance induction with a high-purity von Willebrand factor containing plasma-derived factor VIII concentrate in a child with hemophilia A with inhibitors. Pediatric Hematology/Oncology and Immunopathology, 2022, 21, 122-126.	0.1	1
359	The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A. Blood Advances, 2023, 7, 620-629.	2.5	12
360	Comprehensive approach to hemophilia. Journal of Health Sciences and Medicine, 2022, 5, 1199-1206.	0.0	1
361	Isolated Variable Domains of an Antibody Can Assemble on Blood Coagulation Factor VIII into a Functional Fv-like Complex. International Journal of Molecular Sciences, 2022, 23, 8134.	1.8	1
362	Management of haemophilia A with inhibitors: A regional crossâ€talk. Haemophilia, 2022, 28, 950-961.	1.0	6

#	Article	IF	Citations
363	Immunogenicity of Current and New Therapies for Hemophilia A. Pharmaceuticals, 2022, 15, 911.	1.7	8
364	Prophylaxis and hemophilia care in LATAM: Baring it allâ€"Highlights from the CLAHT 2021 symposium. EJHaem, 0, , .	0.4	0
365	Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication. Blood Advances, 2023, 7, 1831-1848.	2.5	1
366	Can T-cell and B-cell excision circles predict development of inhibitors in pediatric hemophilia A?. Pediatric Research, 0, , .	1.1	0
367	The More Recent History of Hemophilia Treatment. Seminars in Thrombosis and Hemostasis, 2022, 48, 904-910.	1.5	13
369	Lowâ€dose immune tolerance induction in children with severe hemophilia A with highâ€titer inhibitors: Type of factor 8 mutation and outcomes. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	1.0	0
370	Past, Present, and Future Options in the Treatment of Hemophilia A. Clinical Laboratory Science: Journal of the American Society for Medical Technology, 2019, 32, ascls.2018001032.	0.1	0
371	Is there any place for replacement therapy of hemophilia A in children in present and future?. Russian Journal of Pediatric Hematology and Oncology, 2022, 9, 56-64.	0.1	0
372	Clinical trials and promising preclinical applications of CRISPR/Cas gene editing. Life Sciences, 2023, 312, 121204.	2.0	4
373	Real-world bleeding outcomes and product utilization in people with severe-type hemophilia A before and after switching to extended half-life rFVIIIFc prophylaxis therapy. International Journal of Hematology, 0, , .	0.7	1
375	Anti-FVIII antibodies in Black and White hemophilia A subjects: do F8 haplotypes play a role?. Blood Advances, 2023, 7, 4983-4998.	2.5	1
376	Hemophilia a patients with inhibitors: Mechanistic insights and novel therapeutic implications. Frontiers in Immunology, 0, 13, .	2.2	1
378	BAY 81-8973 Efficacy and Safety in Previously Untreated and Minimally Treated Children with Severe Hemophilia A: The LEOPOLD Kids Trial. Thrombosis and Haemostasis, 2023, 123, 027-039.	1.8	0
379	Low-dose immune tolerance induction therapy in severe hemophilia a children in China: Starting earlier resulted in better inhibitor eradication outcomes. Thrombosis Research, 2023, 225, 33-38.	0.8	0
380	Different inhibitor incidence for individual factor VIII concentrates in 1076 previously untreated patients with severe hemophilia A: data from the PedNet cohort. Journal of Thrombosis and Haemostasis, 2023, 21, 700-703.	1.9	1
381	Complement protein C3a enhances adaptive immune responses towards FVIII products. Haematologica, 0, , .	1.7	0
382	Haemophilia A: A Review of Clinical Manifestations, Treatment, Mutations, and the Development of Inhibitors. Hematology Reports, 2023, 15, 130-150.	0.3	0
384	Qualification of Hemophilia Treatment Centers to Enable Multi-Center Studies of Gene Expression Signatures in Blood Cells from Pediatric Patients. Journal of Clinical Medicine, 2023, 12, 2080.	1.0	0

#	Article	IF	Citations
385	New directions to develop therapies for people with hemophilia. Expert Review of Hematology, 2023, 16, 417-433.	1.0	4
386	InÂvitro effects of combining Mim8 with factor VIII, FVIIa, and activated prothrombin complex concentrates in thrombin generation assays. Journal of Thrombosis and Haemostasis, 2023, , .	1.9	2